Baird lowered the firm’s price target on Vor Bio (VOR) to $14 from $22 and keeps an Outperform rating on the shares. The firm said Vor announced 3Q24 financials and provided pipeline updates, which were generally in line with expectations ahead of key ASH data.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR:
Questions or Comments about the article? Write to editor@tipranks.com